Emerging concepts in HIV pre-exposure prophylaxis: focus on twice-yearly lenacapavir

The persistent global burden of HIV and the need for more flexible, durable prevention strategies have accelerated the development of long-acting pre-exposure prophylaxis (PrEP) options. Lenacapavir (LEN), a first-in-class capsid inhibitor, is approved as a twice-yearly subcutaneous injection for HI...

Celý popis

Podrobná bibliografie

Hlavní autor:	Sarah L Anderson
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BioExcel Publishing Ltd 2026-02-01
Edice:	Drugs in Context
Témata:	antiviral agents hiv infections lenacapavir long-acting pharmaceuticals pre-exposure prophylaxis
On-line přístup:	https://www.drugsincontext.com/emerging-concepts-in-hiv-pre-exposure-prophylaxis-focus-on-twice-yearly-lenacapavir/
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!